INTRODUCTION
Anti-platelet therapy for patients following a diagnosis of MI consists of aspirin and a P2Y 12 receptor antagonists irrespective of whether the diagnosis is STEMI or NSTEMI. Recent data conducted in humans and in relevant murine models of MI and peripheral arterial disease (PAD) suggests the platelet phenotype, platelet receptor signaling, and responsiveness to antiplatelet medications are quite different from healthy platelets in which anti-platelet agents are first characterized (1) (2) (3) (4) (5) (6) .
Patients with established vascular disease have a heightened risk of recurrent atherothrombotic events, often manifesting as (NSTEMI) (7) . Observational studies indicate long-term mortality for patients with NSTEMI remains greater than STEMI irrespective of appropriate cardiac catheterization and revascularization utilization (8, 9) . We previously reported in a small patient cohort that platelets from patients with NSTEMI show differences in post-receptor signal transduction pathways including the platelet PAR1 pathway compared to platelets from patients with STEMI or from healthy individuals (1) .
Cardiovascular physiology and pharmacological responses in men and women are not the same (10) . Myocardial function and the ability to withstand ischemic insult may also differ in women compared to men (11) (12) (13) (14) . Women who present with acute and chronic cardiovascular diseases remain under-studied and, therefore, are likely under-treated (15) . The clinical presentation, management, and response to therapies for MI may also be different in women compared to men (16, 17) . Women with NSTEMI are less likely to be treated with an early invasive strategy than men though, curiously, this did not contribute to increased mortality in women (18) .
Anti-platelet therapy prescribed following acute MI or as maintenance therapy in patients with coronary artery disease (CAD) does not consider whether the patient is male or female. A recent meta-analysis suggested that low dose aspirin may be less efficacious in men compared to women based on weight and height being associated with adverse vascular events or bleeding diatheses (19) . We rather hypothesized that sex-specific differences in platelet signaling in health and at the time of MI may account for such population-based observations. To test this hypothesis, we evaluated platelet signaling following agonist stimulation in healthy women and men, comparing those responses to platelet signaling in women and men presenting with acute MI. We then interrogated our data to determine independent clinical variables predicting platelet responses though specific surface receptors for which prescription medications exist.
METHODS

HUMAN STUDIES
Healthy volunteer subjects aged 19-89 were recruited by answering a posted document, and all were free from anti-platelet agent use or vasoactive substances. The post-MI patient cohort included STEMI and NSTEMI patients. Delayed consent was granted for patients presenting with STEMI (within 24 hours of presentation) to avoid interfering with the door-to-balloon time.
This also provided platelets obtained before they were affected by P2Y 12 receptor antagonist load, and before angiography or coronary instrumentation. The sample was discarded if the patient declined to enroll and sign the consent form. For patients with NSTEMI, subjects were already in the emergency department or hospital for 1-10 hours and identified by elevated plasma cardiac troponin (plasma value greater than the 99 th percentile of a healthy population with a 10% assay coefficient of variation CV) and symptoms consistent with cardiac chest pain. (healthy subjects).
PLATELET FUNCTION
We used flow cytometry with measurement of platelet surface P-selectin to assess platelet function in a dose-dependent manner, as we have described previously (1) . L of labeled CD62P (P-selectin) antibody was incubated in the dark for 30 minutes. Samples were fixed in 2% formalin, then platelet surface P-selectin was quantified on an Accuri Flow Cytometer (BD Biosciences). Data was then processed through FloJo (Ashland, Oregon).
PLATELET SPREADING
Glass slides were pre-coated the prior day with fresh human fibrinogen at a final concentration of 2.5 mg/mL in PBS. The fibrinogen-coated slides were washed three times with PBS and then incubated for 1 hour at 37°C with PRP from healthy subjects. Platelets were then fixed in 4% formaldehyde in 0.25% Triton X-100 for 20 minutes and then incubated with 0.3 μM rhodamine phalloidin for 30
minutes. The glass slides were then gently washed three times with PBS, and then imaged with a confocal microscope. The investigator was blinded to the identity of the platelets until the analysis was complete and decoding occurred. Random fields of platelets were imaged, and the average platelet area was calculated using ImageJ software (NIH). 
EXPERIMENTAL ANIMALS
Mouse colony: All animal protocols were approved by the University Committee on Animal
Resources (UCAR). Eight-week-old male and female wild-type C57/BL6 mice were used in this study. The left anterior descending coronary artery (LAD) was surgically ligated as we previously described to create a model of chronic ischemia which chronically activates platelets over several days (2) . Retro-orbital blood collected into heparinized Tyrodes solution as described by us previously was used to isolate mouse PRP(2). Methylene blue was injected and LV perfusion and ischemic area of risk confirmed the integrity of the model as we reported previously (2).
STATISTICAL ANALYSIS
Dichotomous clinical variables are presented as frequencies. Continuous clinical variables are presented as mean with standard error of the mean (SEM) unless otherwise stated. Normalcy of all data were firstly evaluated by the Shapiro-Wilk test. For Gaussian-distributed data between 2 comparative groups, the t-test was used to assess for a difference between groups, and for nonGaussian-distributed data, the Mann-Whitney U test was used. For Gaussian-distributed data in 3 or more groups, 1-way ANOVA then the Bonferroni multiple comparisons test was used, otherwise the Kruskal-Wallis test followed by Dunn post-test was used. Multivariate regression analyses were conducted in the post-MI cohort to identify clinical variables independently associated with platelet activation. Three separate models were performed to test for male/female and NSTEMI/STEMI specific differences in platelet reactivity through PAR1, the thromboxane receptor, and the P2Y 12 receptor. The model included the following variables: sex, STEMI or NSTEMI (MI), age (rounded to nearest decade), hyperlipidemia (cholesterol), chronic kidney disease (renal function), chronic venous insufficiency (venous disease), hypertension (blood pressure), presently on platelet inhibitors (anti-platelet therapy), and peripheral artery disease (arterial disease.) Results include the parameter estimate ± 95% confidence interval (C.I.). Significance was accepted as a P value <0.05. Analyses were conducted using SAS version 9.4 (SAS Institute, North Carolina). Graphical data and simple group comparisons were illustrated using GraphPad Prism 7 (GraphPad Software, Inc., La Jolla, CA).
RESULTS
Sex differences in platelet signaling in healthy humans
Platelet signaling in healthy individuals was interrogated by dose-response curves using platelet surface agonists for which orally-available antagonists are available. Platelet PAR1 receptor signaling was assessed by TRAP-6, the thromboxane receptor by U46619, and the P2Y 12 receptor by ADP. Platelets from women generally displayed more agonist responsiveness than men through the platelet receptors studied. The platelet thromboxane signaling pathway, which is indirectly inhibited by aspirin, was strikingly more active in platelets from healthy women compared to men (Figure 1 ). Spreading of human platelets on an extracellular fibrinogen matrix, which is suggestive of glycoprotein IIb/IIIa (GPIIb/IIIa) activativity, was enhanced in women compared to men ( Figure 2 ).
Sex differences in platelet signaling post-MI in humans
Using a single platelet receptor agonist concentration which best evoked platelet responses in healthy platelets, we examined platelet activation in women and men presenting acutely with STEMI and NSTEMI prior to receiving a loading dose of a P2Y 12 receptor antagonist and prior to coronary angiography. Table 1 
Sex differences in platelet surface receptor expression in humans
Using flow cytometry, we assessed whether differences in platelet surface PAR1, thromboxane, and P2Y 12 receptor expression were responsible for the observed changes in platelet activation in women and men in health and following NSTEMI. Mild differences in platelet PAR1 receptor expression were noted with increased expression in stimulated healthy men(P=0.02) but not healthy women (P=0.08) platelets, and in both stimulated male NSTEMI platelets (P=0.023) and in stimulated female NSTEMI platelets (P=0.019). Platelet PAR1 expression in unstimulated healthy platelets compared to unstimulated NSTEMI platelet was similar in men and mildly increased in women (P=0.03) ( Figure S2 ). Alterations in platelet surface receptor expression, therefore, is less likely to explain the profound increase in platelet PAR1 signaling observed in men presenting with NSTEMI ( Figures 3-4) .
Platelet surface thromboxane receptor expression was only greater in unstimulated NSTEMI platelets isolated from men compared to unstimulated healthy platelets (P=0.01), and for stimulated healthy platelets compared to stimulated NSTEMI platelets in men (P=0.04) ( Figure S3 ). Only stimulated male NSTEMI platelets showed greater P2Y 12 surface expression (105 vs. 61 MFI, P=0.045) ( Figure S4 ).
Sex differences in platelet signaling in healthy mice and in mice following MI
The mature platelet has a surprisingly dynamic protein expression profile which may be responsible for changes in platelet phenotype. Based on changes in agonist sensitivity, the response to anti-platelet agents, and platelet proteomic profiles, we concluded that the mature platelet phenotype can change in vivo and in vitro in humans and in mouse models of hypoxic and ischemic disease (21) . Given our present observation that platelet thrombin signaling differs in men and women in health and following MI, we employed an established murine MI model Figure 5A ). This observation is particularly striking given the area at risk in the ischemic left ventricle was slightly greater in females at the time of MI compared to males. This suggests an intrinsic difference in platelet signaling for males and females in the disease rather than the severity of the disease model ( Figure 5B ).
DISCUSSION
To our knowledge, the present study is the first to directly compare platelet signaling in women with men in healthy conditions and in the post-MI environment. We purposefully investigated only platelet signaling pathways for which anti-platelet and anti-thrombotic agents exist to maximize the translational impact of the study. Comparing platelet signaling in health to the immediate post-MI environment, a reciprocal switch in platelet activation through proteaseactivated receptors occurs, with attenuated signaling in women and increased signaling in men during MI. This was further corroborated by reproducing this sex-specific observation in mice, suggesting a conserved rather than a species-specific physiologic phenomenon.
Our sex-specific observations in platelet signaling following MI was most pronounced in NSTEMI compared to STEMI, validating previous reports that platelets in each condition may be fundamentally different (1, 22, 23) . By multivariate regression analysis, it is potentially revealing that NSTEMI independently predicted both platelet PAR1 and thromboxane, but not P2Y 12 receptor signaling. This suggests that blocking platelet thromboxane production with aspirin and blocking the platelet PAR1 receptor directly with an antagonist such as vorapaxar, or
indirectly with an anticoagulant, may be most beneficial in NSTEMI as implied in the original COMPASS study (24) .
Women have historically been under-studied in scientific investigations. We confirmed the observation of Becker et al. that thromboxane-mediated platelet activation in health is more significant for women than men (25) . Well-designed population-based studies failed to show that aspirin confers significant protection from adverse cardiovascular events in men when used for primary preventive purposes (26, 27) . When used for primary prevention in females, aspirin does, however, confer some protection against thrombotic stroke (28) . A recent meta-analysis of five studies by Rothwell et al. suggested low dose aspirin may lack a protective effect in the majority of men due to possible under-dosing (19) . While body mass and height tend to be greater in men, this association does not necessarily confirm causation. Based on our present results, we propose that healthy women have a platelet phenotype which is particularly sensitive to activation through thromboxane-mediated signaling which is blocked when aspirin irreversibly acetylates cyclooxygenase, and so healthy women may therefore derive more benefit from aspirin for primary prevention (29) . When platelet thromboxane production is blocked, there is a reduction in thromboxane secretion and, platelet 'auto-activation', which is an important amplification step in thrombus formation, is attenuated (30) . A very recent study in a murine mode of arterial thrombosis confirmed that lower doses of aspirin (81-100 mg)
satisfactorily attenuate the thrombotic potential of platelets through thromboxane inhibition, while higher doses of aspirin, by preventing platelet prostacyclin production, promote bleeding (31) . It is noteworthy, however, that the investigators only studied male mice. We therefore caution that there is neither clear evidence to suggest empirically increasing the dose of aspirin in men confers additional protective properties from thrombosis nor is there evidence to suggest that high dose aspirin promotes more bleeding in women. Conducting a study in healthy women and men with low (81 mg), intermediate (162 mg), and high (325 mg) dose aspirin, assessing thromboxane B 2 to assess adherence and efficacy, then evaluating several methods of platelet activation through the thromboxane receptor will be required to truly prove whether a divergent platelet phenotype in women and men is responsible for the differences in cardiovascular outcomes observed with aspirin use.
We observed that platelet GPIIb/IIIa activation in healthy human platelets is greater in females. The CRUSADE study revealed female patients with NSTEMI treated with an intravenous GPIIb/IIIa antagonist have more bleeding than males, suggesting a sex-specific difference in GPIIb/IIIa signaling (17) . At this time, intravenous GPIIb/IIIa antagonist dosing regimens do not account for gender-specific differences in platelet activation. Future investigations should focus on a gender-dependent effect of GPIIb/IIIa antagonists in the post-MI setting and on cardiovascular outcomes.
Off-target effects of anti-platelet agents and unexpected lack of efficacy in patients with certain demographic profiles or in certain clinical scenarios has been extensively reported.
Single nucleotide polymorphisms in genes encoding enzymes for P2Y 12 antagonist metabolism, opiate-mediated alterations in P2Y 12 antagonist absorption, and metabolic disease-mediated alterations in the P2Y 12 receptor conformation are proposed mechanism for failure of clopidogrel and ticagrelor to exert their anti-platelet affect (4, 32, 33) . Enteric-coated aspirin resulting in delayed absorption, changes in the activity of drug transporters, and possible under-dosing are proposed mechanisms to explain an alteration in the efficacy of aspirin (19) (34) . Determination of a gender-specific difference in these clinical situations as we present here is a logical extension of those previous studies. We previously reported that proteomic profiles, agonist sensitivity, and anti-platelet medication efficacy are altered in humans and in murine models of MI and peripheral artery disease (1, 3) . We now suggest, based on the present data, that platelets in patients with acute MI are primed toward augmented PAR signaling in men. Reasons for augmented platelet activation in males at the time of MI are unlikely to be explained only by sexspecific changes in platelet surface receptor density which we report here, but likely involve several alterations in post-receptor signal transduction pathways in male and female platelets.
Further studies should focus on examining downstream (post-receptor) signal transduction pathways in platelets.
The present data supports our prior observations in a small patient cohort that platelets from patients with NSTEMI preferentially activate through PAR1 compared to platelets from patients with STEMI, though clinical and demographic variables to account for the observation were unclear (1). We now identify sex as an independent predictor of platelet PAR1 signaling following NSTEMI. The Acute Coronary Syndromes (TRACER) study suggested that a PAR1
antagonist added to dual anti-platelet therapy (DAPT) had some benefit in reducing adverse cardiovascular events with an increased risk of major bleeding (35) , while a PAR1 antagonist alone in patients with established vascular disease significantly prevented arterial thrombosis and limb ischemia (36) . Similarly, the MANAGE study showed that direct thrombin inhibition with dabigatran in patients with vascular disease and evidence of myocardial injury at the time of noncardiac surgery conferred protection from thrombosis and vascular death (37) . Focusing more on inhibiting platelet Protease Activated Receptors (PARs) or circulating thrombin as a mechanistic intervention-particularly in males in the peri-MI environment-is logical based on the current findings and previous investigations.
Using a Factor Xa inhibitor alone in the ATLAS ACS2 study (38) or in combination with aspirin in the COMPASS study, there was a dramatic reduction in atheroembolic events and improved mortality in patients with known vascular disease (39) . It is noteworthy that these studies showed outcomes that were several-fold greater in men than women. The present study and our clinical experience is that twice as many males as females present with acute MI.
Together, these observations raise the possibility that indirectly blocking thrombin with a Xa inhibitor may show the most survival benefit in males as reported (24, 39) . Moreover, since Xa inhibitors indirectly inhibit circulating downstream Factor IIa (thrombin) activity (40), it is striking that our present study confirmed in both humans and in mice that thrombin-mediated platelet activation is especially important in males in the immediate post-MI environment.
STUDY LIMITATIONS
This investigation provides mechanistic insight that platelets from males and females respond differently to surface receptors for which drugs are available in health and following MI.
A prospective investigation in which platelet thromboxane receptor signaling is blocked directly (aspirin) and platelet thrombin signaling is blocked directly (thrombin antagonist, PAR1
antagonist) or indirectly (Factor Xa inhibitor) will be required to assess whether sex-specific antithrombotic therapy should be employed acutely to affect mortality in patients with acute MI.
Sex-specific differences in platelet signaling should also be examined in patients with chronic vascular disease such as CAD and PAD in whom recurrent atheroembolic events involving platelets are common.
CONCLUSIONS
Inhibiting both platelet thrombin and thromboxane signaling in multiple vascular beds could be one mechanism for improving outcomes in stable vascular disease and in patients transitioning off dual anti-platelet therapy between 6 to 24 months post-MI. Our results indicate that greater attention should be directed towards whether changes in the platelet phenotype in women and men are responsible for differences in outcomes and responsiveness to anti-platelet medications.
PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: Platelet thromboxane receptor and
glycoprotein IIb/IIIa signaling were especially active in platelets from healthy females compared to males. Platelet PAR1 was strongly activated in males and attenuated in females at the time of MI compared to healthy conditions. TRANSLATRIONAL OUTLOOK: Platelet phenotype and function are different in health and in the immediate post-MI environment for women and men, and therefore may shows differences in the response to anti-platelet agents. The predilection of platelets from healthy women to be activated by thromboxane pathway signaling may explain why aspirin appears to be more protective for stroke prevention compared to men. NSTEMI independently predicted platelet PAR1 as well as platelet thromboxane signaling but not P2Y 12 receptor signaling, providing
